Design and Development of Electrospun Patch Platform Technology of the Delivery of Carvedilol in the Oral Mucosa
Abstract: Carvedilol, sold under the brand name Coreg among others, is a beta blocker medication, that may be prescribed for the treatment of high blood pressure (hypertension) and chronic heart failure with reduced ejection fraction (also known as HFrEF or systolic heart failure). Beta-blockers as a collective medication class are not recommended as routine first-line treatment of high blood pressure for all patients, due to evidence demonstrating less effective cardiovascular protection and a less favourable safety profile when compared to other classes of blood pressure-lowering medications. A transdermal patch is a medicated adhesive patch that is placed on the skin to deliver a specific dose of medication through the skin and into the bloodstream. An advantage of a transdermal drug delivery route over other types of medication delivery (such as oral, topical, intravenous, or intramuscular) is that the patch provides a controlled release of the medication into the patient, usually through either a porous membrane covering a reservoir of medication or through body heat melting thin layers of medication embedded in the adhesive. Carvedilol is a therapeutic alternative on the World Health Organization's List of Essential Medicines. It is available as a generic medication.
Keywords: Carvedilol Drug, Patch Technology, By Oral Mucosa
How to Cite?: Krishan Kant, "Design and Development of Electrospun Patch Platform Technology of the Delivery of Carvedilol in the Oral Mucosa", Volume 15 Issue 10, October 2026, International Journal of Science and Research (IJSR), Pages: 1158-1164, https://www.ijsr.net/getabstract.php?paperid=SR261017114716, DOI: https://dx.doi.org/10.21275/SR261017114716